Pilot Efficacy and Safety Study of AQX-1125 in Atopic Dermatitis
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the effect of 12 weeks of treatment with
once daily administration of AQX-1125 compared to placebo on change from baseline in Total
Lesion Symptom Score in subjects with mild to moderate atopic dermatitis